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Multi-morbidities are Not a Driving Factor for an
Increase of COPD-Related 30-Day Readmission
Risk
This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease
Shuo-yu Lin
Hong Xue
Yangyang Deng
Askar Chukmaitov
Department of Health Behavior and
Policy, School of Medicine, Virginia
Commonwealth University, Richmond,
VA, USA
Background and Objective: Chronic obstructive pulmonary disease (COPD) is the third
leading cause of death in the United States. COPD is expensive to treat, whereas the quality
of care is difficult to evaluate due to the high prevalence of multi-morbidity among COPD
patients. In the US, the Hospital Readmissions Reduction Program (HRRP) was initiated by
the Centers for Medicare and Medicaid Services to penalize hospitals for excessive 30-day
readmission rates for six diseases, including COPD. This study examines the difference in
30-day readmission risk between COPD patients with and without comorbidities.
Methods: In this retrospective cohort study, we used Cox regression to estimate the hazard
ratio of 30-day readmission rates for COPD patients who had no comorbidity and those who
had one, two or three, or four or more comorbidities. We controlled for individual, hospital
and geographic factors. Data came from three sources: Healthcare Cost and Utilization
Project (HCUP) State Inpatient Databases (SID), Area Health Resources Files (AHRF) and
the American Hospital Association’s (AHA's) annual survey database for the year of 2013.
Results: COPD patients with comorbidities were less likely to be readmitted within 30 days
relative to patients without comorbidities (aHR from 0.84 to 0.87, p < 0.05). In a stratified
analysis, female patients with one comorbidity had a lower risk of 30-day readmission
compared to female patients without comorbidity (aHR = 0.80, p < 0.05). Patients with
public insurance who had comorbidities were less likely to be readmitted within 30 days in
comparison with those who had no comorbidity (aHR from 0.79 to 0.84, p < 0.05).
Conclusion: COPD patients with comorbidities had a lower risk of 30-day readmission
compared with patients without comorbidity. Future research could use a different study
design to identify the effectiveness of the HRRP.
Keywords: multi-morbidities, readmission, gender difference, health insurance, all-payer
claims databases
Introduction
Chronic Obstructive Pulmonary Disease (COPD), according to World Health
Organization (WHO) and Global Initiative for Chronic Obstructive Lung Disease
(GOLD), is a lung disease characterized by persistent chronic obstruction of lung
airflow that interferes with normal breathing and/or alveolar abnormalities usually
caused by significant exposure to noxious particulars or gases.1,2 In 2011, COPD
was the third leading cause of death in the United States, and the second leading
cause of reduced disability-adjusted life years (DALYs), trailing only ischemic
heart disease.3,4 Moreover, the total costs of COPD treatment are projected to
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increase from $32.1 billion in 2010 to $49.9 billion by
2020, mostly due to the increase of disease severity, hos-
pital stays, and more complex multimorbidity.5,6
Multimorbidity, defined as patients having two or more
coexisting diseases, is one of the key reasons for rising
health care costs and a loss of productivity in the United
States.7 The majority of COPD patients have comorbid-
ities: 68% had at least one, and 16% had two or more,
while 30% of those admitted with COPD acute exacerba-
tion had four or more comorbidities.8,9 These multimor-
bidities were associated with higher health care costs, ED
visits, mortality, and readmissions.10–12
Readmission serves as one important indicator measur-
ing the quality and utilization of expensive inpatient care
that adds to total health care costs. In 2012, due to a trend
of increasing inpatient total charges for 30-day COPD-
related readmissions,13 the Centers for Medicare and
Medicaid services (CMS) initiated the Hospital
Readmissions Reduction Program (HRRP). By penalizing
hospitals for excessive 30-day readmission rates for six
disease- or procedure-specific indicators, this program
aimed to decrease excessive medical costs. One of these
six indicators is COPD.
Reducing 30-day COPD-related readmission, however,
can be challenging, especially for patients with comorbid-
ities, because no existing guidance is applicable. Even
though comorbidities are important factors in predicting
the risk of 30-day readmission,10,14 the management and
the medical intervention in COPD patients with comorbid-
ities is not clearly established worldwide.15 Research has
shown that COPD comorbid with other diseases, such as
heart disease,16,17 depression16,17 and diabetes,18 could
increase the risk of 30-day readmission. However, none of
these studies were representative, and none took multimor-
bidity into consideration.16–18 Two studies analyzed only
one state within the US (one in Florida and the other in
California),16,17 and the other study only used data from
private health insurance plans.18 Furthermore, they solely
considered the impact of one comorbidity and did not eval-
uate how the increasing number of comorbidities would
affect 30-day readmission. Given the importance of disease
complexity in COPD-related 30-day readmission, evaluat-
ing and comparing the impact of multimorbidity on 30-day
readmission is substantial. However, only limited studies to
date have examined the risk of 30-day readmission between
COPD patients with and without additional comorbidities.
We hypothesized that COPD patients who had comorbid-
ities would show higher 30-day readmission risk compared
to those who did not present comorbidities, and the risk
would raise as the number of comorbidities increased. The
primary aim of this study is to test this hypothesis.
In addition, this study has two secondary aims. First, this
study tests the gender effect. Prior research reported that
male and female patients were different in terms of COPD-
related 30-day readmission.7,11,19 Males were more likely to
be readmitted,19,20 whereas females had fewer comorbid-
ities and might be undertreated for COPD, itself.21
Although gender plays an important role in COPD read-
mission, few studies have navigated how gender might
affect the COPD-related 30-day readmission rate among
patients with and without additional comorbidities. We
hypothesized that both male and female COPD patients
with comorbidities were more likely to be readmitted, com-
pared to male patients without comorbidities. Second, this
study differentiates the effects between having public
(Medicare and Medicaid) or private and other health insur-
ance. Evidence has shown that COPD patients enrolled in
public insurance programs had a higher risk of being read-
mitted, because Medicaid enrollees tend to represent lower
socioeconomic groups (cite), while Medicare beneficiaries
represent an older population,19 and both groups generally
have more complex health needs. We hypothesized that,
among patients with public insurance, those with comorbid-
ities had higher risks of being readmitted within 30 days, as
compared to COPD patients without comorbidities.
Methods
Study Population
We used all-payer admissions in the Healthcare Cost and
Utilization Project (HCUP) of the State Inpatient
Databases (SID) in this multistate retrospective cohort
study. HCUP SID are state-specific files that contain all
inpatient admission records in participating states, encom-
passing more than 95% of all US hospital discharges. The
SID are well suited for research that requires enumeration
of hospitals and discharges within geographic areas or
states.22 Because of this feature, it is one of the strengths
of using SID to evaluate the 30-day readmission risks
among COPD patients.
Our study population consisted of COPD patients from
nine states, including Arkansas, Florida, Iowa, Massachusetts,
New Jersey, Nebraska, New York, Utah, and Washington.
Patients were aged 40 years or older23 and had been admitted
into hospitals between January 1, 2013, to December 31, 2013.
We followed the Agency for Healthcare Research and Quality
Lin et al Dovepress
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(AHRQ) guidance and software in developing an index to
identify COPD patients—those who had International
Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) codes 491.0, 491.1, 491.20,
491.21, 491.22, 491.8, 491.9 [chronic bronchitis], 492.0,
492.8 [emphysema], 494.0, 494.1 [bronchiectasis] or 496.xx
[COPD, unspecified].24 Even though bronchiectasis differs
from COPD clinically, we still include bronchiectasis as part
of COPD definition. Bronchiectasis and COPD clinically can
be overlapped, and sometimes bronchiectasis can be misre-
ported as COPD.25 According to the definition of Prevention
Quality Indicator 05 (PQI 05) of COPD, provided by AHRQ,
bronchiectasis is included.26 We chose their first admission
within 2013 as the index date and excluded those who had
asthma, who had planned readmissions, who were discharged
against medical advice, who reported a same-day referral at
the same hospitals for the same principal diagnosis, and who
were transferred to short-term hospitals.
This study was approved by Virginia Commonwealth
University’s (VCU) institutional review board (IRB).
Informed consent was waived by the VCU IRB, because
we used administrative data collected in 2013 in the form
of a limited data set. Patients’ individual IDs were de-
identified in State Inpatient Databases (SID) to ensure data
confidentiality. This study was carried out in accordance
with the principles of the Declaration of Helsinki.
Outcomes
The main outcome was COPD-related 30-day readmission.
We defined COPD-related 30-day readmission as patients
who had unplanned readmission within 30 days after dis-
charge and had COPD as their principal diagnosis.
Covariates
Covariates were extracted from three data sources: HCUP
SID, Area Health Resources Files (AHRF) and the American
Hospital Association (AHA) annual survey database. The
major independent variable was a set of comorbidities. We
used Elixhauser methodology to develop comorbidity mea-
sures. The AHRQprovides Elixhauser Comorbidity software
to identify major chronic comorbidities for risk adjustment of
the HCUP SID. The software creates 29 binary variables,
excluding complications,27,28 based on the International
Classification of Diseases (ICD) 9th revision, clinical mod-
ification (ICD-9-CM). Congestive heart failure, diabetes,
depression, and peripheral vascular disease that frequently
occur in COPD patients are among those identified.27,29 We
used administrative data that were compiled after the primary
diagnoses were confirmed. Thus, we excluded all secondary
COPD diagnosis as we wanted to assess the effects of other
comorbidities on patients with primary COPD diagnosis.
Using these 29 comorbidity indicators, we created 4mutually
exclusive comorbidity indicator variables.30 First, we identi-
fied patients who had only a COPD diagnosis, meaning they
did not have any comorbidities. Second, we then categorized
the rest of COPD patients into having one, two to three, and
four or more comorbidities.
Previous studies suggested that many factors could
influence COPD-related 30-day readmissions. In this
study, we categorized them into three levels: individual
patient, hospital, and geographic. Individual-level factors,
obtained from HCUP SID, included gender, race, age and
types of primary insurance payer.7,16,31 Hospital-level fac-
tors included number of beds; teaching hospital; residency
training approval hospital; hospital location and Medicare
Accountable Care Organization (ACO) types: Pioneer or
Medicare Shared Savings Program (MSSP);32,33 informa-
tion collected from the AHA Annual Survey and the level
of implementation of health information technology, col-
lected from the Health Information and Management
System Society. Geographic level factors consisted of med-
ian household income (reported by quartiles of the patient’s
ZIP code and acquired from AHRF), Herfindahl–Hirschman
index (defined as the sum of square market shares of
inpatient days measured in a county,34 which was obtained
from AHA survey), and state-fixed effects.35,36
Statistical Analysis
To access the impact of different levels of factors on COPD-
related 30-day readmission, we built our models cumulatively.
First, we built up a crudemodelwhere only comorbiditieswere
included (model 1). Second, we considered outcomes were
confounded by individual patient characteristics and added
them into the regression model (model 2). Third, we then
added hospital factors into model 2 in creating model 3 to
examine howhospital-level factors, after controlling individual
factors, would affect outcome estimates. Finally, we added
geographic level factors into model 3 in creating model 4.
While we were not able to distinguish effects between indivi-
dual factors and other two (hospital and geographic factors), by
creating models aggregately, we could evaluate what level of
factors could best explain unobservable variations.
We estimated hazards of 30-day readmission, using Cox
regression to compute crude and adjusted hazard ratios
(HRs) with 95% CIs for the individual outcomes associated
with four comorbidity groups, and with COPD patients
Dovepress Lin et al
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having no comorbidities as the reference group. First, with-
out controlling any other covariates but comorbidities, we
estimated the crude hazard ratio of 30-day readmission.
Second, we compute adjusted hazard ratios considering
outcomes first confounded only by individual characteris-
tics. Then, we added hospital- and geographic level fac-
tors, cumulatively. Finally, we stratified by gender and
primary insurance payer types to examine their effects,
respectively. With the assumption underline Cox regres-
sion, we assume the hazard functions for different levels of
comorbidities are proportional for all time points.
Results
Basic Characteristics
The final analyzable sample, following the sample selection
process showed in Figure 1, contains 9982 COPD-diagnosed
patients. Among them, 824 patients have only a COPD
diagnosis, 1839 patients have COPD and one comorbidity
diagnosis, 4606 patients have two to three comorbidities,
and 2713 patients have four or more comorbidities.
As shown in Table 1, on individual-level characteristics,
comorbidity groups distribute differently among COPD
patients according to gender, age, race, and insurance
types. Males are less likely to be diagnosed with comorbid-
ities compared to females. However, as the number of
comorbidities increases, the percentage of diagnosed
males decreases (from 49.39% with zero comorbidity to
42.39% with four or more comorbidities, p < 0.0001); in
contrast, the proportion of females increases (from 50.61%
to 57.61%, p < 0.0001). Regarding age, elderly people are
more likely to have more complex comorbidities. The aver-
age age for patients who have no comorbidity is 65.77
Figure 1 Sample selection process.
Note: *Incomplete data imply those who had missing value in controlling variables.
Lin et al Dovepress
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Table 1 Sample Characteristics, by Comorbidity Categorizations, January 2013–December 2013
Comorbidities COPD
Non 1 2 to 3 4 or More
N % N % N % N % p
All 824 100 1839 100 4606 100 2713 100
Individual factors
Gender
Male 407 49.39 845 45.95 2051 44.53 1150 42.39 <0.0001
Female 417 50.61 994 54.05 2555 55.47 1563 57.61
Agea (in years) 65.77 11.55 67.82 11.41 69.34 11.41 71 11.61 <0.0001
Race
White 722 87.62 1541 83.8 3678 79.85 2119 78.11 <0.0001
Black 32 3.88 139 7.56 452 9.81 313 11.54
Hispanic 47 5.7 110 5.98 343 7.45 203 7.48
Other 23 2.79 49 2.66 133 2.89 78 2.88
Insurance types
Public 621 75.36 1505 81.84 4042 87.76 2468 90.97 <0.0001
Private 203 24.64 334 18.16 564 12.24 245 9.03
Hospital factors
Bed size
6–199 beds 320 38.83 650 35.35 1412 30.66 744 27.42 <0.0001
200–349 beds 270 32.77 635 34.53 1760 38.21 1062 39.14
500 or more beds 234 28.4 554 30.13 1434 31.13 907 33.43
Teaching hospital
Yes 137 16.63 345 18.76 930 20.19 615 22.67 0.0013
No 687 83.37 1494 81.24 3676 79.81 2098 77.33
Residency training hospital
Yes 305 37.01 720 39.15 1943 42.18 1230 45.34 <0.0001
No 519 62.99 1119 60.85 2663 57.82 1483 54.66
Rural hospital
Yes 117 14.2 234 12.72 501 10.88 251 9.25 0.0001
No 707 85.8 1605 87.28 4105 89.12 2462 90.75
Basic health IT
No 8 0.97 22 1.2 38 0.83 25 0.92 0.573
Partially 329 39.93 742 40.35 1857 40.32 1100 40.55
Fully 487 59.1 1075 58.46 2711 58.86 1588 58.53
Geographic factors
ACO types
Pioneer
Yes 39 4.73 102 5.55 281 6.1 202 7.45 0.004
No 785 95.27 1737 94.45 4325 93.9 2511 92.55
MSSP
Yes 109 13.23 317 17.24 868 18.84 545 20.09 0.0001
No 715 86.77 1522 82.76 3738 81.16 2168 79.91
Median income
1st 259 31.43 583 31.7 1486 32.26 908 33.47 0.0572
2nd 224 27.18 517 28.11 1314 28.53 743 27.39
(Continued)
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years, and increases to 71 for those who have four or more
comorbidities (p < 0.0001). The majority of these patients
are white (>78%), and more than 75% have public insur-
ance (Medicare or Medicaid). Public insurance enrollees
tend to have more complex conditions (75%without comor-
bidity compared to 90.7%with four or more comorbidities).
On the other hand, patients with private or other types of
health insurance tend to have fewer comorbidities.
In terms of hospital-level characteristics, COPD patients
who have more comorbidities on average stay longer in
hospitals (3.78 days without comorbidity compared to
5.27 with four or more comorbidities, p < 0.0001).
Additionally, urban and teaching hospitals are more likely
to admit patients with more comorbidities.
Regarding geographic level characteristics, as the num-
ber of comorbidities increases, the proportion of Medicare
Accountable Care Organization (ACO) enrollees increases,
and the health care markets become less concentrated.
Risk of 30-Day Readmission
Table 2 shows the crude and adjusted hazard ratio (HR) of
30-day readmission among comorbid COPD patients.
Model 1 presents the crude HR, showing that, although
COPD patients without comorbidities have a slightly
lower risk of readmission (HR = 0.91), the risk of 30-
day readmission between COPD patients with and without
comorbidities does not differ significantly (p value from
0.06 to 0.1).
When taking into account individual-level factors
(model 2), the hazard of 30-day readmission differs
between COPD patients without comorbidities and those
who have comorbidities. Compared to COPD patients
without comorbidities, those COPD patients with one
(aHR = 0.84, 95% CI: 0.72–0.96, p = 0.013) or two to
three (aHR = 0.87, 95% CI: 0.76–0.98, p = 0.026)
comorbidities have significantly lower risks of being read-
mitted within 30 days. For COPD patients have four or
more comorbidities (aHR=0.87, 95% CI: 0.76–1.00, p =
0.05), while the 30-day readmission risk is also lower as
compared to those who did not have comorbidities, this
risk reduction is not statistically significant. Additionally,
these effects remain consistent when we further add hos-
pital- and geographic level factors (models 3 and 4),
implying that our basic model could sufficiently explain
the majority of possible variations. We observe a slight
dose response that, as the number of comorbidities grows,
the risk of being readmitted increases from 0.84 to 0.87.
We also observe that the risk of 30-day readmission
differs by gender in which females have lower 30-day
readmission risks (aHR = 0.91, 95% CI: 0.85–0.98) than
males. In addition, we find the median income among
different geographic areas could influence 30-day read-
mission risk. Although only patients living in areas with
the highest median income report a significantly lower risk
of 30-day readmission (aHR = 0.89, 95% CI: 0.80–1.00,
p = 0.041), we still observe that the risk of being read-
mitted decreases as the median income increases.
Stratified Analysis
We conducted stratified analyses to test two secondary
hypotheses. First, we evaluate the gender effect. As shown
in Table 2, the 30-day readmission risk performs differently
between males and females. We conducted a stratified ana-
lysis to evaluate the gender effect (Table 3). Table 3 shows
that females with comorbidities, compared to those without,
are less likely to be readmitted within 30 days (aHR from
0.80 to 0.85). A similar trend also appears among males.
Interestingly, regardless of how many comorbidities they
have, we observed that males with comorbidities, as
Table 1 (Continued).
Comorbidities COPD
Non 1 2 to 3 4 or More
N % N % N % N % p
All 824 100 1839 100 4606 100 2713 100
3rd 219 26.58 443 24.09 1060 23.01 620 22.85
4th 122 14.81 296 16.1 746 16.2 442 16.29
HHIa 0.51 0.29 0.48 0.28 0.47 0.27 0.44 0.26 <0.0001
Notes: aPresented in mean and standard error. Boldface indicates statistical significance (p < 0.05)
Abbreviation: ACO, Accountable Care Organization.
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Table 2 COPD Comorbidity Categorization and 30-Day Readmission Risk, by Different Levels of Controlling Variables
30-Day Readmission
Model 1 2 3 4
Crude 1 + Individual Factors 2 + Hospital Factors 3 + Geographic Factors
HRa 95% CI p aHRb 95% CI p aHRb 95% CI p aHRb 95% CI p
COPD 1 Ref. 1 Ref. 1 Ref. 1
COPD + 1 0.91 (0.81, 1.02) 0.09 0.84* (0.72, 0.96) 0.013 0.84* (0.73, 0.96) 0.014 0.83* (0.72, 0.96) 0.011
COPD + 2–3 0.91 (0.82, 1.01) 0.064 0.87* (0.76, 0.98) 0.026 0.87* (0.77, 0.99) 0.032 0.87* (0.76, 0.99) 0.03
COPD + 4 and more 0.91 (0.82, 1.02) 0.096 0.87 (0.76, 1.00) 0.050 0.88 (0.77, 1.01) 0.068 0.88 (0.77, 1.01) 0.059
Individual factors
Gender
Male 1 Ref. 1 Ref. 1 Ref.
Female 0.91* (0.85, 0.98) 0.010 0.91* (0.85, 0.98) 0.013 0.92* (0.85, 0.98) 0.014
Age 1 (1.00, 1.00) 0.488 1 (1.00, 1.00) 0.421 1 (1.00, 1.00) 0.336
Race
White 1 Ref. 1 Ref. 1 Ref.
Black 0.87* (0.76, 0.98) 0.027 0.87* (0.77, 0.99) 0.036 0.86* (0.75, 0.98) 0.023
Hispanic 0.96 (0.83, 1.10) 0.535 0.96 (0.84, 1.11) 0.615 0.96 (0.83, 1.11) 0.588
Other 0.94 (0.76, 1.17) 0.596 0.95 (0.77, 1.17) 0.616 0.95 (0.77, 1.18) 0.653
Insurance types
Public 1 Ref. 1 Ref. 1 Ref.
Private and others 0.96 (0.86, 1.07) 0.436 0.96 (0.86, 1.07) 0.487 0.98 (0.88, 1.09) 0.654
Hospital level
Bed size
6–199 beds 1 Ref. 1 Ref.
200–349 beds 0.98 (0.89, 1.07) 0.629 1 (0.92, 1.10) 0.92
500 or more beds 0.98 (0.87, 1.11) 0.794 1.01 (0.89, 1.15) 0.849
Teaching hospital
No 1 Ref. 1 Ref.
Yes 1.03 (0.94, 1.14) 0.483 1.03 (0.94, 1.14) 0.505
Residency training hospital
No 1 Ref. 1 Ref.
Yes 0.94 (0.84, 1.05) 0.271 0.93 (0.83, 1.05) 0.23
Rural hospital
No 1 Ref. 1 Ref. 0.424
Yes 1.1 (0.98, 1.23) 0.111 1.05 (0.93, 1.18) 0.427
Basic health IT
No 1 Ref. 1 Ref.
Partially 1.15 (0.79, 1.70) 0.464 1.09 (0.74, 1.61) 0.65
Fully 1.14 (0.78, 1.67) 0.507 1.06 (0.72, 1.56) 0.774
ACO types
Pioneer
No 1 Ref. 1 Ref.
Yes 0.81* (0.69, 0.95) 0.010 0.85 (0.72, 1.01) 0.069
MSSP
No 1 Ref. 1 Ref.
Yes 1.01 (0.92, 1.11) 0.846 0.98 (0.88, 1.08) 0.675
(Continued)
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compared to females within the same comorbidity group,
seem to have a higher chance of being readmitted within 30
days.
Second, we also assess the impact of health insurance on
30-day readmission stratified by public (Medicare and
Medicaid), private, and other health insurance type (shown
in Table 3. COPD patients with Medicare or Medicaid
coverage, if having comorbidities, are less likely to be read-
mitted within 30 days (aHR from 0.79 to 0.84)). This result
differs from what we expected. Regarding private and other
health insurance, however, we observe that the number of
comorbidities does not affect 30-day readmission risks,
which is in accordance with our hypothesis.
Discussion
After the first discharge in 2013, this study showed that
COPD patients who had comorbidities were less likely to
be readmitted within 30 days, compared to those who had
no comorbidities. However, we observed a small incre-
mental effect showing that the more comorbidities patients
had, the higher the risk of 30-day readmission they would
experience, which echoes past findings.37 The stratified
analysis indicated that gender and primary insurance
payer effects existed. Females who had comorbidities,
compared to those who had no comorbidities, had
a lower 30-day readmission risk. In comparison, males
had a higher 30-day readmission risk than females, regard-
less of the number of comorbidities they had. Comorbid
patients with public insurance, compared to those who had
no comorbidities, had a lower 30-day readmission risk. In
addition, as the number of comorbidities grew, the risk of
readmission for those patients increased slightly.
Though our results might contradict previous
findings,20 they are aligned with some existing evidence.
First, as shown in Figure 1, we found that 16,201 patients
(16.3%) were readmitted within 30 days, which concurred
with past findings of 19.2%.19 Moreover, the distribution
of comorbidity categories was also similar to previous
results.30 Second, by using SID and Elixhauser comorbid-
ities variables, previous studies have shown that among
comorbid COPD patients— including congestive heart
failure, lung cancer, weight loss, deficiency anemias,
hypertension, diabetes, hypothyroidism, lymphoma, alco-
hol abuse, obesity, chronic kidney disease and obstructive
sleep apnea—the risk of 30-day all-cause or COPD-related
readmission did not differ from patients without
comorbidities.13,16,17 One possible explanation is that
a primary COPD diagnosis among comorbid patients
could motivate them to modify their health behaviors by
trying to increase physical activities and monitoring their
diet.38 Furthermore, COPD patients with comorbidities
often consulted family physicians more, which may in
Table 2 (Continued).
30-Day Readmission
Model 1 2 3 4
Crude 1 + Individual Factors 2 + Hospital Factors 3 + Geographic Factors
HRa 95% CI p aHRb 95% CI p aHRb 95% CI p aHRb 95% CI p
Geographic level
Median income
1st 1 Ref.
2nd 0.97 (0.88, 1.06) 0.495
3rd 0.91 (0.83, 1.01) 0.071
4th 0.89* (0.80, 1.00) 0.042
HHI 1.07 (0.90, 1.26) 0.438
State-fixed effects
AR 1 Ref.
FL 1.09 (0.94, 1.25) 0.252
IA 1.41* (1.19, 1.68) 0
MA 1.03 (0.87, 1.22) 0.747
NY 1.08 (0.94, 1.25) 0.269
UT 0.5 (0.13, 2.03) 0.336
WA 1.23 (0.98, 1.53) 0.072
Notes: *p value < 0.05; aHR, crude hazard ratio. baHR, adjusted hazard ratio.
Abbreviations: AR, Arkansas; FL, Florida; IA, Iowa; MA, Massachusetts; NY, New York; UT, Utah; WA, Washington.
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turn have resulted in better health outcomes.38 Diabetes
patients with COPD were more likely to receive preferen-
tial care, for example.39
Two probable reasons can explain why our findings
differ from earlier literature. First, our estimates are more
restricted, as compared to other studies which also
acquired readmissions from SID. We only consider read-
missions after first discharge in 2013, whereas previous
studies consider readmissions not only after the first
discharge.13,16 As a result, more severe patients could
have more readmissions. These could lead to an overesti-
mate of the risk of 30-day readmission. Second, it could be
due to the difference of study design. Past literature gen-
erate estimates from pooling several years of SID together,
2005–2011 or 2009–2014 for example. By pooling several
years of data, it could increase statistical power. However,
it could also eliminate potential policy impacts— Hospital
Readmissions Reduction Program (HRRP) for instance,
since neither of these two studies included years as
dummy variables.13,16
From physicians’ perspectives, there may be a greater
perceived need for older persons with multimorbidity to
reduce readmission, especially since the HRRP was
launched in 2012 and began penalizing hospitals with
excess COPD readmission as of October 2014. CMS
accesses a hospital’s performance relative to other hospitals
with a similar proportion of patients who are dually eligible
for Medicare and full-benefit Medicaid. After calculating
the payment adjustment factor and component results for
each hospital based on their performance within a certain
period, payment reductions are applied to all Medicare fee-
for-service (FFS) base operating diagnosis-related group
(DRG) payments. The payment is capped at 3%.40
Physicians had higher incentives in 2013 to reduce 30-day
readmissions among comorbid COPD patients. A study
analyzing Florida’s COPD patients found that COPD-
related 30-day readmissions decreased between 2012 and
2013, from 7.9% to 7.6%.13 Although we did not directly
test the effect of HRRP, we thought two reverse directions
could explain this result. On the one hand, the penalty could
have encouraged hospitals and physicians to start to provide
better care for COPD patients. Under pressure from clearly
defined penalties, hospitals started to design readmission
reduction programs,41 and programs bearing a higher risk
may increase the likelihood of reducing preventable
readmissions.34 But, on the other hand, hospitals may
lower readmissions by shifting care to other high-resource
settings such as observation stays or emergency room (ED)
visits rather than delivering higher quality care, because
these settings were exempt from the HRRP.20
The stratified analysis showed a gender effect. In this
study, we found females, compared to males, had a higher
likelihood of reporting multimorbidity. Prior research sug-
gested that men were more likely to self-report having
COPD.42 In addition, we also found that females, compared
to males, had a lower 30-day readmission risk. This finding
concurred with previous results, showing females had lower
30-day all-cause readmissions43 and fewer ICU admissions
due to COPD exacerbation in the previous year.21 Males,
based on review and retrospective study, in accordance with
our estimates, had a higher frequency of readmission.44,45
Because females were less likely to self-report COPD and
have COPD as a primary diagnosis, when women were
readmitted within 30 days their reasons for readmission
may not have been caused by COPD.
Additionally, the stratified analysis showed COPD
patients with Medicare and Medicaid coverage had
a lower risk of 30-day readmission, compared to those
with private and other types of insurance. Previous studies
have shown that, for patients discharged with hospice
services, those who were dual Medicare- and Medicaid-
eligible were less likely to be readmitted within 30 days
compared with other insurances.46 One possible reason
could be the effect of HRRP. Through initiating negative
Table 3 COPD Comorbidity Categorization and 30-Day Readmission Risk, Stratified by Gender and Insurance Types
30-Day Readmissiona
Female Male Publicb Private and Otherb
aHRc 95% CI p aHRc 95% CI p aHRc 95% CI p aHRc 95% CI p
COPD 1 Ref. 1 Ref. 1 Ref. 1 Ref.
COPD + 1 0.79* (0.65, 0.97) 0.024 0.89 (0.72, 1.09) 0.241 0.79** (0.67, 0.93) 0.004 1 (0.73, 1.36) 0.986
COPD + 2–3 0.85 (0.71, 1.01) 0.069 0.9 (0.75, 1.08) 0.269 0.84* (0.74, 0.98) 0.025 0.91 (0.68, 1.21) 0.511
COPD + 4 and more 0.86 (0.71, 1.03) 0.105 0.92 (0.75, 1.12) 0.387 0.85* (0.73, 0.99) 0.039 0.91 (0.65, 1.29) 0.61
Notes: p value *<0.05, **<0.01; aThe model adjusted for individual-, hospital- and geographic level factors; bPublic insurance includes Medicare and Medicaid enrollees;
Private and other includes private, self-pay, no charge. caHR, adjusted hazard ratio.
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repercussions, this program reduces payments to hospitals
with excess COPD readmissions. To avoid this, health care
providers have been incentivized to provide a better qual-
ity of care that might reduce 30-day readmission risk for
patients enrolled in Medicare or Medicaid. Although pri-
mary data suggest some impact on readmissions, more
research is needed to examine the effect of HRRP under
an implementation science framework.20,47
Limitations
Our study has several potential limitations. First, this analysis
was based on administrative data; hence, coding, sampling
errors and hospital misclassifications were possible. Second,
the diagnoses of COPD and comorbidities were based on
ICD-9-CM codes in the SID data and did not have clinical
confirmation. Nevertheless, SID data are accurate and have
been used previously for studying readmission risk.30 Third,
there may also be some potential selection bias, since only
patients with complete data were included in our study.
However, as we presented in Supplemental Table S1, the
covariates of patients with incomplete data were distributed
similar to those who had complete data. Fourth, in line with
other observational studies, our model might be influenced
by unobservable variables. For example, the severity of
COPD at the time of admission, the outpatient chronic dis-
ease management, and the degree of patients’ self-
management after discharge. Fifth, we only included 1 year
as our observation time, which may affect the statistical
power of the analysis. Nevertheless, we included data from
nine states of the US, which encompassed an adequate sam-
ple population. Sixth, our data were not randomly selected
from all US patients with COPD and thus its generalizability
may be influenced. Nevertheless, the nine states we chose
covered large numbers of patients and different geographic
locations, which would tend to increase our estimates’ gen-
eralizability. In addition, as we provided in Supplemental
Table S2, the COPD categorizations distributed similarly
between samples that were analyzed and patients who met
our excluding criteria. Finally, there might be a selection bias
present. However, as shown in Supplemental Table S3, we
used Heckman selection model that showed no selection
problem.
Conclusion
In this large, all-payer, population-based retrospective study,
we found that, compared with non-comorbid patients, COPD
patients with comorbidities had a lower risk of 30-day read-
mission. Additionally, we also found females and public
insurance enrollees had a lower risk of 30-day readmission.
In sum, our estimates suggested that COPD patients with
comorbidities, being females, and enrolled in public insurance
programs were less likely to have unplanned readmission
within 30 days of first discharge in 2013. Our findings cannot
distinguish whether the lower 30-day readmission risk among
COPD patients with multimorbidity could be attributed to
better care quality or underdiagnoses and delays in treatment.
Future research could encompass more years in order to assess
the policy effect and could incorporate outpatient and emer-
gency department data to assess hospitals’ strategies to
decrease readmissions and patients’ adherence to treatments.
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